Recent 8-K filings for BLGO

• May 6, 2026, 7:59 PM ET other materiality 0.15 neutral item 7.01item 9.01

  BioLargo CEO holds Discord town hall; transcript filed as 8-K

  CEO Dennis Calvert participated in a May 5, 2026 town hall on Discord; transcript and investor summary furnished.

• May 4, 2026, 7:59 PM ET other materiality 0.20 neutral item 7.01item 9.01

  BioLargo CEO to host town hall on Discord May 5; transcript to follow

  Town hall on May 5, 2026 at 1:00 PM PT hosted on BioLargo Shareholder Discord channel.

• March 25, 2026, 7:59 PM ET other material materiality 0.60 neutral item 1.01item 3.02item 9.01 ◈ Equity Issuances◈ Material Agreements

  BioLargo enters $10M equity purchase agreement with Clearthink Capital Partners

  Clearthink commits to buy up to $10M of BioLargo common stock over 36 months under a Strata purchase agreement.

• March 5, 2026, 6:59 PM ET earnings materiality 0.70 negative item 7.01item 9.01

  BioLargo 2025 revenue falls 56% to $7.8M; net loss widens to $15.2M

  Total revenue dropped to $7.8M from $17.8M in 2024 due to termination of largest customer's license.

• November 18, 2025, 6:59 PM ET other material materiality 0.50 neutral item 8.01item 9.01

  BioLargo issues 624,383 shares to officers for salary; locked until $40M revenue or $300M cap

  Two officers converted $99,901 of unpaid salary/expenses into 624,383 shares at $0.16/share.

• November 14, 2025, 6:59 PM ET other material materiality 0.25 neutral item 7.01item 9.01

  BioLargo to present investor webcast on Nov 14, 2025 with slides attached

  Investor webcast scheduled for Nov 14, 2025 at 1:30 PM PT.

• October 20, 2025, 7:59 PM ET other materiality 0.15 neutral item 7.01item 9.01

  BioLargo presents at LD Micro Main Event; no material new information disclosed

  Company presented slides at LD Micro Main Event on October 20, 2025 in San Diego.

• September 25, 2025, 7:59 PM ET other material materiality 0.80 negative item 1.02item 2.06item 7.01item 9.01

  BioLargo revokes Pooph license due to $3.8M default; expects substantial impairment of $3.49M note receivable

  Pooph owed BioLargo approximately $3.8M in past-due royalties and product invoices; BioLargo revoked license on Sept 24, 2025.

• August 15, 2025, 7:59 PM ET other material materiality 0.15 neutral item 7.01item 9.01

  BioLargo presents slides at investor conference; no material new details in filing

  Slides were presented at a webcast investor conference on August 15, 2025 at 8:00 AM PT.

• July 23, 2025, 7:59 PM ET other material materiality 0.75 neutral item 7.01item 9.01

  BioLargo mid-year update: Clyra distribution deals, Cellinity MOUs, PFAS project; Pooph sales drag

  Clyra Medical secured distribution agreements covering 6,100 hospitals, 6,300 ASCs, 2,200 wound care clinics; raised $3.3M in new capital.

• June 25, 2025, 7:59 PM ET other material materiality 0.55 neutral item 5.07item 7.01item 9.01

  BioLargo shareholders approve reverse split authorization; board has no immediate plans

  All seven director nominees elected, including Dennis Calvert, Kenneth Code, Linda Park.

• May 15, 2025, 7:59 PM ET other material materiality 0.20 neutral item 7.01item 9.01

  BioLargo presents at investor webcast; no financial details in filing

  Slide deck presented at webcast investor conference on May 15, 2025 at 1:30 PM PT.

• March 31, 2025, 7:59 PM ET earnings materiality 0.65 positive item 7.01item 9.01

  BioLargo reports record 2024 revenues of $17.8M, up 45% YoY; net loss narrows 6%

  Revenue $17.779M, up 45% from 2023; tenth consecutive year of revenue growth.

• November 15, 2024, 6:59 PM ET earnings materiality 0.65 positive item 7.01item 9.01

  BioLargo Q3: YTD revenue up 80% to $14.1M; net loss narrows

  Year-to-date revenue $14.1M, up 80% YoY; Q3 revenue $4.4M, up 63% YoY.

• August 15, 2024, 7:59 PM ET other materiality 0.05 neutral item 7.01item 9.01

  BioLargo files slide deck from May 2024 conference; no new material data

  Presentation from a May 14, 2024 investor webcast is now filed on Form 8-K.

• June 20, 2024, 7:59 PM ET other material materiality 0.15 neutral item 5.07item 9.01

  BioLargo shareholders elect all seven directors, approve executive compensation, auditor, and 2024 equity plan

  All seven director nominees elected: Dennis Calvert, Kenneth Code, Dennis Marshall, Joseph Provenzano, Jack Strommen, Linda Park, Christina Bray.

• June 13, 2024, 7:59 PM ET other material materiality 0.10 neutral item 7.01item 9.01

  BioLargo presents slides at annual meeting; no extractable data

  Annual stockholder meeting held June 13, 2024; presentation slides furnished.

• May 15, 2024, 7:59 PM ET earnings materiality 0.65 positive item 7.01item 9.01

  BioLargo reports record Q1 revenue, positive operating cash flow of $481K

  Q1 2024 revenue $4.76M, up 28% YoY and 9% QoQ; generated $481K positive operating cash flow.

• January 22, 2024, 6:59 PM ET other material materiality 0.80 positive item 7.01item 9.01

  BioLargo Doubles Annual Revenues for Second Consecutive Year in 2023

  2023 annual revenues more than doubled 2022, driven by Pooph pet odor control product sales.

• January 10, 2024, 6:59 PM ET other materiality 0.15 neutral item 7.01item 9.01

  BioLargo to present at EmergingGrowth.com investor conference; no financial results disclosed in filing

  Company will present slide deck at webcast conference on January 10, 2024, 9:00 AM PT.

• January 5, 2024, 6:59 PM ET other materiality 0.50 neutral item 4.01item 9.01 ◈ Auditor Changes ×2

  BioLargo dismisses Haskell & White, engages Hacker Johnson as auditor for FY 2023

  Audit committee approved Hacker Johnson & Smith PA as independent auditor for fiscal 2023, effective immediately.

• November 21, 2023, 6:59 PM ET earnings materiality 0.30 neutral item 7.01item 9.01

  BioLargo holds earnings call Nov 20; no financial details in 8-K

  BioLargo presented slides at its earnings call on November 20, 2023 at 3:00 PM PT.

• October 4, 2023, 7:59 PM ET other materiality 0.20 neutral item 7.01item 9.01

  BioLargo presents at LD Micro investor conference on October 4, 2023

  Presentation slides furnished as Exhibit 99.1; no financial results disclosed in filing.

• June 12, 2023, 7:59 PM ET other materiality 0.15 neutral item 5.07item 9.01 ◈ Shareholder Votes ×3

  BioLargo stockholders elect all 7 directors, approve say-on-pay and auditor ratification

  All 7 director nominees elected; votes for ranged from 80.6M to 82.7M.

• June 9, 2023, 7:59 PM ET other material materiality 0.85 positive item 7.01item 9.01

  BioLargo Q1 revenue up 78% QoQ; Pooph generates $27M D2C sales in 18 months

  Q1 revenue up 78% QoQ and 130% YoY; net cash flow near breakeven; net loss ~$400k (non-cash).

• June 6, 2023, 7:59 PM ET other materiality 0.10 neutral item 7.01item 9.01

  BioLargo files slides for annual meeting; no material financial details disclosed

  Filing reports Regulation FD disclosure of presentation slides at annual stockholder meeting on June 6, 2023.

• May 18, 2023, 7:59 PM ET other material materiality 0.10 neutral item 7.01item 9.01

  BioLargo presents slides at May 18, 2023 earnings call; no financial details in filing text

  Company held earnings call on May 18, 2023.

• May 9, 2023, 7:59 PM ET other material materiality 0.65 positive item 7.01item 9.01

  BioLargo CEO projects Q1 revenue near $4M, Pooph sales driving growth

  Q4 2022 company-wide revenue grew 132% QoQ; Q1 2023 revenue expected just under $4M (3x YoY).

• April 4, 2023, 7:59 PM ET earnings materiality 0.20 neutral item 7.01item 9.01

  BioLargo presents slides at Q1 2023 earnings call; no specific results in filing text

  Company furnished an image-based slide deck as Exhibit 99.1 under Regulation FD.

• March 27, 2023, 7:59 PM ET leadership materiality 0.35 neutral item 1.01item 9.01

  BioLargo extends CFO Charles Dargan's engagement through Jan 2024; grants option for 300,000 shares

  CFO Charles K. Dargan II's engagement extended one year to January 31, 2024.

• March 20, 2023, 7:59 PM ET earnings materiality 0.75 positive item 7.01item 9.01

  BioLargo expects Q1 2023 revenue >4x YoY, seventh consecutive quarterly growth record

  Q1 2023 preliminary revenues expected to surpass Q4 2022 record; QoQ growth >50%.

• December 19, 2022, 6:59 PM ET other material materiality 0.60 neutral item 1.01item 3.02item 9.01 ◈ Material Agreements ×2

  BioLargo secures $10M equity line from Lincoln Park Capital; issues 1.25M commitment shares

  BioLargo entered purchase agreement with Lincoln Park Capital for up to $10M of common stock over 36 months.

• November 3, 2022, 7:59 PM ET leadership materiality 0.50 neutral item 5.02item 7.01item 9.01 ◈ executive_change ×4

  BioLargo appoints Linda Park and Christina Bray to board; Runyan and Roberts retire

  Linda Park, corporate secretary of Edwards Lifesciences, and Christina Bray, CEO of Bluedot Energies, join board effective Nov 1, 2022.

• October 31, 2022, 7:59 PM ET earnings materiality 0.55 positive item 7.01item 9.01

  BioLargo reports Q3 2022 revenue of ~$1.5M, up 111% YoY; record quarter

  Revenue approximately $1.5M, 13% sequential increase from Q2 and 111% YoY gain.

• August 5, 2022, 7:59 PM ET earnings materiality 0.60 positive item 7.01item 9.01

  BioLargo Q2 2022 revenue ~$1.3M, up 185% YoY; preliminary figures

  Q2 revenue ~$1.3M, up 37% sequentially and 185% vs Q2 2021.

• June 7, 2022, 7:59 PM ET other materiality 0.50 neutral item 5.03item 5.07item 9.01

  BioLargo shareholders approve increase in authorized shares to 550M and authorize reverse stock split

  Authorized common shares increased from 400M to 550M, effective June 7, 2022.

• June 2, 2022, 7:59 PM ET other material materiality 0.10 neutral item 7.01item 9.01

  BioLargo files 8-K for annual meeting slide presentation; no text content available

  Filed Item 7.01 to disclose slides presented at June 2, 2022 annual meeting.

• May 19, 2022, 7:59 PM ET other material materiality 0.65 positive item 7.01item 9.01

  BioLargo reports record Q1 revenue of $965k; ONM subsidiary turns first profitable quarter

  Record company-wide Q1 revenue $965k (+69% YoY); ONM Environmental revenue $598k (+87%) with $13k operating profit (first profitable quarter).

• April 20, 2022, 7:59 PM ET other material materiality 0.70 positive item 7.01item 9.01

  BioLargo reports record Q1 2022 revenue of ~$900k; awarded feasibility contract for waste-to-energy plant

  Q1 2022 revenue approx. $900k, up ~60% YoY; ONM Environmental record ~$550k, engineering subsidiary ~$350k.

• April 4, 2022, 7:59 PM ET earnings materiality 0.70 positive item 7.01item 9.01

  BioLargo 2021 revenue $2.53M (+4%), net loss down 29% to $6.9M, debt cut to $0.68M

  Revenue of $2,531,000 for FY2021, a 4% increase from 2020; Q4 revenue $784,000 (+10% QoQ).

• March 24, 2022, 7:59 PM ET leadership materiality 0.30 neutral item 1.01item 9.01

  BioLargo extends CFO engagement through Jan 2023; grants 300k-share option at $0.24

  CFO Charles K. Dargan II engagement extended one year to January 31, 2023.

• March 8, 2022, 6:59 PM ET other material materiality 0.75 neutral item 9.01

  BioLargo unwinds 2018 Scion deal, transfers SkinDisc IP back, cancels $1.25M note

  BioLargo and Clyra assign SkinDisc IP (patents, trademark) back to Scion; Scion keeps 2M BioLargo shares.

Executive changes

Materiality & sentiment trend

Max materiality 0.85 · Median 0.50 · Most common event other_material

12 positive 2 negative 28 neutral

source · BLGO on sec.gov